Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer in another Japanese molecular imaging deal

This article was originally published in Scrip

Executive Summary

Bayer Schering Pharma(BSP) has licensed exclusive global development and marketing rights to a group of cancer imaging molecules developed by the Japanese firm Hamamatsu Photonics. The radionucleotide-labelled tracers are taken up by carrier molecules highly expressed on malignant tumour cells and are used in combination with positron emission tomography (PET). The hope is that they will aid earlier and more specific identification of malignant cells, BSP said. It is the second Japanese imaging alliance in recent months for the German group. Last year, BSP acquired from Nagasaki University similar rights to molecules used in the PET imaging and diagnosis of Alzheimer's disease (Scrip Online, September 12th, 2009).

You may also be interested in...



Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem

The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?

Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili

Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.

Asahi Paying $1.3bn For One-Product Veloxis

Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.

Topics

UsernamePublicRestriction

Register

SC007602

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel